Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.

The relapse risk in patients with MOGAD is generally lower than that in patients with AQP4-Ab-positive NMOSD, especially 5 years after onset. Meanwhile, relapses later than 10 years from onset are not rare in both diseases.